Filing Scope and Business Context
Important identification issue: The supplied filing is Selecta Biosciences, Inc. (NASDAQ: SELB), not Cartesian Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2019, filed March 12, 2020. The requested “2019 Q4” period is reflected only through quarterly data within the annual filing.
Selecta was a clinical-stage biopharmaceutical company developing its ImmTOR nanoparticle platform to induce antigen-specific immune tolerance and reduce anti-drug antibodies against biologic therapies. Its lead candidate was SEL-212 for chronic refractory gout. The company also pursued ImmTOR applications in gene therapy through collaborations with AskBio, Spark Therapeutics, and CureCN.
Financial Performance and Position
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Grant and collaboration revenue | $6.7 million | $0.9 million | +$5.8 million |
| Operating expenses | $59.1 million | $65.9 million | -$6.8 million |
| Research and development expense | $42.7 million | $47.7 million | -$4.9 million |
| General and administrative expense | $16.4 million | $18.2 million | -$1.8 million |
| Loss from operations | $52.5 million | $65.0 million | Improved by $12.6 million |
| Net loss | $55.4 million | $65.3 million | Improved by $10.0 million |
| Basic and diluted loss per share | $1.22 loss | $2.92 loss | Improved |
| Cash flow used in operations | $51.4 million | $59.2 million | Improved by $7.8 million |
Revenue consisted entirely of collaboration and grant revenue; the company had no product sales and did not expect product revenue for the foreseeable future. Approximately $6.7 million of 2019 revenue resulted from the expiration of Spark’s additional target-option period, with less than $0.1 million from shipments to Spark.
Cash, cash equivalents, and restricted cash totaled $91.6 million at December 31, 2019, compared with $37.7 million at December 31, 2018. Cash and cash equivalents were $89.9 million. The company raised $105.0 million through financing activities, including $30.9 million from a January public offering, approximately $5.7 million from an August private placement, approximately $65.6 million in net proceeds from the December financing, and $1.0 million from at-the-market sales.
Debt outstanding was $18.9 million at year-end, with all amounts classified as current because of going-concern considerations and the lender’s subjective acceleration clause. Total warrant liabilities were $41.5 million, primarily related to the December 2019 financing. Stockholders’ equity was $8.4 million, compared with a deficit of $5.4 million in 2018. Accumulated deficit reached $335.8 million.
Fourth-quarter 2019 revenue was $6.7 million, operating expenses were $19.2 million, and net loss was $14.9 million, compared with fourth-quarter 2018 revenue of $0.9 million, operating expenses of $15.4 million, and net loss of $14.7 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased substantially because of recognition of deferred collaboration revenue associated with the expiration of Spark’s target options and related deliveries.
- Research and development expense declined 10%, primarily because of completed or deprioritized programs, headcount reductions, and lower internal costs, partly offset by higher SEL-212 spending.
- General and administrative expense declined 10% because of lower compensation, stock-based compensation, patent fees, and professional fees.
- Net loss improved despite the absence of product revenue, but the company remained dependent on external financing.
- Cash increased by $53.9 million, driven primarily by equity financing, while operating cash burn remained substantial.
- The December financing materially increased shares outstanding and introduced 31.3 million warrants, including 23.0 million liability-classified warrants and 8.3 million pre-funded warrants.
- The company entered into an AskBio license agreement for Pompe disease applications, with $7.0 million of upfront fees, up to $237.0 million in development and commercial milestones, and tiered royalties. It had received $2.0 million by year-end.
- The company entered into an amendment with MIT that tolled a Phase 3 diligence obligation until the earlier of a specified date in the second quarter of 2020 or a future written amendment.
Guidance, Outlook, Risks, and Unusual Items
- Selecta expected to report top-line data from the approximately 150-patient Phase 2 COMPARE trial of SEL-212 versus KRYSTEXXA in the third quarter of 2020.
- The company planned to begin two Phase 3 SEL-212 trials in the second half of 2020 and stated that additional capital would be required to complete the program.
- Management stated that year-end cash and investments were expected to fund operating and capital requirements into the first quarter of 2021, but concluded that substantial doubt existed regarding the company’s ability to continue as a going concern within one year after filing.
- Key risks included clinical-trial failure, regulatory delay or non-approval, adverse events, limited patient enrollment, manufacturing dependence on 3SBio in China, potential supply-chain disruption from the novel coronavirus, reliance on collaborators, and intellectual-property license requirements.
- The company reported a prior serious safety event in the discontinued SEL-403 oncology program: a patient death associated with pneumonitis, followed by an FDA clinical hold and termination of the LMB-100 license. The program was no longer being pursued.
- SEL-212 remained investigational and had not received regulatory approval. Clinical results cited by management were early-stage or Phase 2 results and were not guarantees of Phase 3 success.
- The company had no material legal proceedings and no off-balance-sheet arrangements reported at year-end.
Most Important Facts for Investors to Verify
- Verify the issuer identity: the supplied filing is for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc.
- Verify the going-concern disclosure and whether subsequent financing or restructuring resolved the stated liquidity uncertainty.
- Review the December 2019 financing, including dilution from 37.6 million shares, 31.3 million warrants, and the $41.5 million warrant liability.
- Confirm the remaining debt obligations, current classification of the $18.9 million loan, collateral provisions, and any lender default or acceleration status.
- Assess whether SEL-212 COMPARE results and the planned Phase 3 program supported regulatory approval and commercial viability.
- Review the MIT license amendment and whether the company satisfied the amended diligence requirements.
- Evaluate the sustainability of collaboration revenue, since 2019 revenue was not product revenue and included a significant non-recurring recognition event.